ArticleApplied biochemistry and biotechnology2025
Long Noncoding RNA SNHG12 Regulates Ischemia/reperfusion (I/R)-mediated Acute Kidney Injury (AKI) Through miR-129-1-3p/Ubiquitin Specific Peptidase 25 axis.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- LncRNASNHG12 regulates the development of diabetic nephropathy through miR-129-5p/IL6ST axis.Molecular biology reports · 2026Article
- Ubiquitin-specific protease 25: a new regulator for cardiovascular and cerebrovascular diseases.Frontiers in cell and developmental biology · 2026Review
- Long Non-coding RNA MIR22HG Alleviates Ischemic Acute Kidney Injury by Targeting the miR-134-5p/NFAT5 axis.Inflammation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveA growing body of evidence suggests the involvement of long noncoding ribose nucleic acids (lncRNAs) in acute kidney injury (AKI). This study focused on the mechanistic role of lncRNA small nucleolar RNA host gene 12 (SNHG12) in ischemia/reperfusion (I/R)-mediated AKI. A model of hypoxia/reoxygenation (H/R) was created using human kidney cells (HK-2). Expression levels of SNHG12 and miR-129-1-3p mRNAs, and USP25 protein were determined through quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blotting analyses, respectively. Furthermore, the relationship between SNHG12 and miR-129-1-3p, as well as miR-129-1-3p and Ubiquitin Specific Peptidase 25 (USP25), was investigated using dual-luciferase reporter gene, RNA pull-down, and immunoprecipitation assays. To further evaluate the role of SNHG12 in AKI, a mouse model was established to study the pathological changes in kidney tissues after SNHG12 knockdown. SNHG12 was upregulated in H/R-induced HK-2 cells and I/R-induced AKI mouse model. Conversely, the expression of miR-129-1-3p showed a significant downregulation. Through dual-luciferase assay and RNA pull-down analysis, it was demonstrated that SNHG12 interacted with miR-129-1-3p, and miR-129-1-3p acted as a negative regulator of USP25. Silencing SNHG12 attenuated the detrimental effect of H/R on HK-2 cells, which was counteracted by miR-129-1-3p antagomir. USP25 overexpression also reversed the effect of miR-129-1-3p on H/R-induced HK-2 cells. SNHG12 knockdown was further found to ameliorate I/R-induced renal injury, apoptosis, oxidative stress, and inflammation in AKI mouse model. SNHG12 was upregulated in I/R-induced AKI and its knockdown ameliorated AKI through the miR-129-1-3p/USP25 axis. SNHG12/miR-129-1-3p/USP25 axis serves as a potential therapeutic target for I/R-related renal injury.
Indexed as
Identifiers
39820927What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.